Stated plainly: early satiety · semaglutide · STEP 5.
I would like help reading this properly rather than being told what conclusion to reach.
I have the full report including the method section, so I can quote specifics if that helps.
What would I need in addition before this supported a decision?
Take it from the STEP 5 adverse-event table by arm, and check the unit before you use it. An incidence can be the proportion of participants who reported the event at least once, or the count of events divided by exposure time, and the two differ by however many people had it repeatedly. Then subtract the placebo arm, because the untreated rate is not zero. And read the discontinuation column beside it: an event that made people leave the trial is under-counted at every later visit, so a low late-timepoint incidence can mean the event was severe rather than rare.
Start with which symptom predominates, because the management diverges sharply even though the mechanism does not.
Fat is the macronutrient that slows emptying most on its own, so a high-fat meal on top of pharmacologically delayed emptying is the combination that produces the worst episodes.
| Event | Active arm | Placebo arm | Timing |
|---|---|---|---|
| Nausea | 40–45 % | 15–20 % | Peaks 1–2 wk after each step |
| Vomiting | 15–25 % | 5–8 % | Follows nausea |
| Diarrhoea | 20–30 % | 10–15 % | Early, variable |
| Constipation | 20–25 % | 8–12 % | Later onset, persistent |
| Discontinuation for GI events | 4–7 % | 1–2 % | Mostly during escalation |
Ranges span agents and doses; read the specific prescribing information for a specific figure.
Gastric emptying of a solid meal can be delayed substantially at initiation. The effect is largest early and attenuates over weeks for the long-acting agents, which is the mechanistic basis for the titration schedule.
Trial-reported incidence and discontinuation rates for gastrointestinal effects are published per agent and per dose and are the appropriate figures to quote.
Nothing here is medical advice.
Smaller meals, less fat, fluids between rather than with. In that order.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsAnswering this needs the titration history, because going faster than the schedule is the single largest modifiable factor.
Symptom prevalence in trials, broadly: nausea a quarter to a half, diarrhoea and constipation each roughly ten to twenty per cent, vomiting rather less, with all rates rising with dose.
Discontinuation for gastrointestinal effects in the trials runs in the low single-figure percentages, which means the great majority of people who experience these effects continue.
Four-weekly titration intervals in the licensed schedules were selected to allow tolerance between escalations.
The caveat is that severe persistent symptoms, particularly with dehydration or severe pain, are clinical and not a matter of waiting them out.
Everything except constipation attenuates. Plan differently for that one.
The short version: dose-related, escalation-concentrated, mostly attenuating except for constipation, and manageable by titration pace more than anything else.
Symptoms that appear for the first time at a stable dose after months are not the ordinary pattern and warrant looking for another explanation.
Concretely, reflux occurs because a slower-emptying stomach retains volume for longer against a lower oesophageal sphincter that has not changed. Smaller meals and not lying down within a few hours are the direct responses.
Dietary fat slowing gastric emptying is basic gastrointestinal physiology and independent of any drug effect.
Most people who report these effects continue. The discontinuation rate is low.
edited 9 Aug 2026 by v_ramaswamy — clarified the distinction between purity and content
This is the group of effects that drives almost all discontinuation in the trial programmes.
The practical hierarchy of interventions: slow the titration, reduce meal size, reduce fat, separate fluids from meals, and only then consider symptomatic treatment.
Gastric emptying studies in this class quantify the delay directly and document its attenuation with continued exposure to the long-acting agents.
New symptoms at a stable dose after months need a different explanation.
The honest answer is that the first eight weeks are the hard part and that most people who get through them stop having the conversation.
Anticipating a slower-than-label titration from the start is a legitimate approach and costs only time, since the exposure ceiling is the same.
Slow the titration first. It is the intervention with the best evidence and the lowest cost.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.